[1] Ueno M, et al. Elinogrel: pharmacological principles, preclinical and early phase clinical testing. Future Cardiol. 2010 Jul;6(4):445-53. DOI:
10.2217/fca.10.67[2] Haberstock-Debic H, et al. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist. J Pharmacol Exp Ther. 2011 Oct;339(1):54-61. DOI:
10.1124/jpet.111.184143
